<p>Kiniksa Pharmaceuticals International（纳斯达克股票代码：KNSA - 获取免费报告）在周五发布的报告中，花旗集团的分析师将其目标股价从 45.00 美元上调至 50.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。花旗集团的目标价暗示该公司当前价格有 31.86% 的上涨潜力。</p>
<p>其他几位股票分析师最近也对 KNSA 发表了评论。富国银行将 Kiniksa Pharmaceuticals International 的目标股价从 42.00 美元上调至 45.00 美元，并在 9 月 25 日的报告中给予该股票 “超配” 评级。杰富瑞金融集团在 7 月 29 日的报告中将 Kiniksa Pharmaceuticals International 的目标股价从 45.00 美元上调至 54.00 美元，并给予该股票 “买入” 评级。扎克斯研究在 10 月 6 日的报告中将 Kiniksa Pharmaceuticals International 的评级从 “强力买入” 下调至 “持有”。Wedbush 在周一的报告中将 Kiniksa Pharmaceuticals International 的目标股价从 38.00 美元上调至 44.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重新发布了 Kiniksa Pharmaceuticals International 的 “持有（c）” 评级。七位分析师对该股票给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 46.86 美元。</p>
<p><strong>查看我们对 Kiniksa Pharmaceuticals International 的最新股票分析</strong></p>
<h2>Kiniksa Pharmaceuticals International 股票表现</h2>
<p>周五中午交易时，KNSA 的股价下跌 1.00 美元，达到 37.92 美元。该股票的交易量为 106,006 股，而其平均交易量为 631,065 股。该公司的市值为 28.1 亿美元，市盈率为 948.49，贝塔值为 0.16。Kiniksa Pharmaceuticals International 的 12 个月低点为 17.82 美元，12 个月高点为 39.43 美元。该公司的 50 日移动平均线为 35.72 美元，200 日移动平均线为 29.60 美元。</p>
<p>Kiniksa Pharmaceuticals International（纳斯达克股票代码：KNSA - 获取免费报告）最后一次发布季度财报是在 7 月 29 日。该公司报告每股收益为 0.23 美元，超出分析师一致预期的 0.18 美元，超出幅度为 0.05 美元。该公司在该季度的收入为 1.568 亿美元，而分析师预期为 1.4521 亿美元。Kiniksa Pharmaceuticals International 的净利润率为 0.90%，股本回报率为 1.05%。Kiniksa Pharmaceuticals International 已设定其 2025 财年的每股收益指导。研究分析师平均预测 Kiniksa Pharmaceuticals International 在当前财年将发布-0.55 美元的每股收益。</p>
<h2>Kiniksa Pharmaceuticals International 的内部买卖</h2>
<p>在相关消息中，内部人士 Ross Moat 在 9 月 4 日的交易中出售了 3,523 股公司的股票。该股票以平均价格 35.31 美元出售，总交易额为 124,397.13 美元。出售后，内部人士持有 9,415 股公司股票，价值 332,443.65 美元。这代表其持股比例减少了 27.23%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，首席会计官 Michael R. Megna 在 9 月 3 日的交易中出售了 11,000 股公司的股票。该股票以平均价格 34.84 美元出售，总交易额为 383,240.00 美元。出售后，首席会计官直接持有 38,011 股公司股票，价值约 1,324,303.24 美元。该交易使其持股比例减少了 22.44%。该交易的披露信息可在此找到。在过去的九十天里，内部人士出售了 596,839 股公司股票，价值 20,357,964 美元。公司内部人士持有 53.48% 的公司股票。</p>
<h2>机构投资者对 Kiniksa Pharmaceuticals International 的看法</h2>
<p>几家对冲基金和其他机构投资者最近对 KNSA 的持仓进行了调整。GAMMA Investing LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 84.8%。GAMMA Investing LLC 现在拥有 1,238 股公司股票，价值 27,000 美元，此前在该期间内增持了 568 股。Wealth Enhancement Advisory Services LLC 在第一季度购买了 Kiniksa Pharmaceuticals International 的新股份，价值 301,000 美元。Asset Management One Co. Ltd.在第一季度购买了 Kiniksa Pharmaceuticals International 的新股份，价值 41,000 美元。Wealthquest Corp 在第一季度购买了 Kiniksa Pharmaceuticals International 的新股份，价值 42,000 美元。最后，AMI Asset Management Corp 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 50.3%。AMI Asset Management Corp 现在拥有 77,688 股公司股票，价值 1,725,000 美元，此前在该期间内增持了 26,010 股。对冲基金和其他机构投资者持有 53.95% 的公司股票。</p>
<h2>关于 Kiniksa Pharmaceuticals International</h2>
<p>（获取免费报告）</p>
<p>Kiniksa Pharmaceuticals, Ltd.是一家生物制药公司，专注于发现、收购、开发和商业化治疗药物，以满足全球面临重大未满足医疗需求的患者的需求。其产品候选包括 ARCALYST，一种针对复发性心包炎的白介素-1α和白介素-1β，复发性心包炎是一种炎症性心血管疾病；Mavrilimumab，一种单克隆抗体抑制剂，已完成巨细胞动脉炎的二期临床试验；Vixarelimab，一种单克隆抗体，目前正在进行针对结节性瘙痒症的 2b 期临床试验，这是一种慢性炎症性皮肤病；以及 KPL-404，一种 CD40-CD154 相互作用的单克隆抗体抑制剂，这是 B 细胞成熟、免疫球蛋白类别转换和 1 型免疫反应所需的 T 细胞共刺激信号。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>即将到来的 IPO 股票锁定期解析</li>
<li>甲骨文的 AI 利润看起来微薄——NBIS 和 CRWV 也有风险吗？</li>
<li>内幕交易 - 你需要知道的事项</li>
<li>雅培实验室十月价格暴跌是买入信号</li>
<li>如何开始投资房地产</li>
<li>为什么富国银行的转型刚刚进入高速档</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Kiniksa Pharmaceuticals International 吗？</h2>
<p>在你考虑 Kiniksa Pharmaceuticals International 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Kiniksa Pharmaceuticals International 并不在名单上。</p>
<p>虽然 Kiniksa Pharmaceuticals International 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KNSA

<p>花旗集团已将 Kiniksa Pharmaceuticals International（纳斯达克代码：KNSA）的目标股价从 45.00 美元上调至 50.00 美元，维持 “买入” 评级。这表明与当前价格相比，潜在上涨幅度为 31.86%。其他分析师也调整了他们的评级，富国银行将目标上调至 45.00 美元，杰富瑞则上调至 54.00 美元。KNSA 的股票交易价格为 37.92 美元，市值为 28.1 亿美元。该公司报告每股收益为 0.23 美元，超出预期，且共识评级为 “适度买入”，平均目标价为 46.86 美元</p>

<p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) had its price target raised by analysts at Citigroup from $45.00 to $50.00 in a report released on Friday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the stock. Citigroup's price objective suggests a potential upside of 31.86% from the company's current price.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International（纳斯达克股票代码：KNSA - 获取免费报告）在周五发布的报告中，花旗集团的分析师将其目标股价从 45.00 美元上调至 50.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。花旗集团的目标价暗示该公司当前价格有 31.86% 的上涨潜力。</p>
</div><p>Several other equities analysts also recently commented on KNSA. Wells Fargo &amp; Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, September 25th. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, July 29th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, October 6th. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday. Finally, Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $46.86.</p>
<div class="lb-trans"><p>其他几位股票分析师最近也对 KNSA 发表了评论。富国银行将 Kiniksa Pharmaceuticals International 的目标股价从 42.00 美元上调至 45.00 美元，并在 9 月 25 日的报告中给予该股票 “超配” 评级。杰富瑞金融集团在 7 月 29 日的报告中将 Kiniksa Pharmaceuticals International 的目标股价从 45.00 美元上调至 54.00 美元，并给予该股票 “买入” 评级。扎克斯研究在 10 月 6 日的报告中将 Kiniksa Pharmaceuticals International 的评级从 “强力买入” 下调至 “持有”。Wedbush 在周一的报告中将 Kiniksa Pharmaceuticals International 的目标股价从 38.00 美元上调至 44.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重新发布了 Kiniksa Pharmaceuticals International 的 “持有（c）” 评级。七位分析师对该股票给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 46.86 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Kiniksa Pharmaceuticals International</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Kiniksa Pharmaceuticals International 的最新股票分析</strong></p>
</div><h2>Kiniksa Pharmaceuticals International Stock Performance</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 股票表现</h2>
</div><p>Shares of KNSA traded down $1.00 during mid-day trading on Friday, reaching $37.92. The stock had a trading volume of 106,006 shares, compared to its average volume of 631,065. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of 948.49 and a beta of 0.16. Kiniksa Pharmaceuticals International has a 12 month low of $17.82 and a 12 month high of $39.43. The business has a fifty day moving average of $35.72 and a 200 day moving average of $29.60.</p>
<div class="lb-trans"><p>周五中午交易时，KNSA 的股价下跌 1.00 美元，达到 37.92 美元。该股票的交易量为 106,006 股，而其平均交易量为 631,065 股。该公司的市值为 28.1 亿美元，市盈率为 948.49，贝塔值为 0.16。Kiniksa Pharmaceuticals International 的 12 个月低点为 17.82 美元，12 个月高点为 39.43 美元。该公司的 50 日移动平均线为 35.72 美元，200 日移动平均线为 29.60 美元。</p>
</div><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, research analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International（纳斯达克股票代码：KNSA - 获取免费报告）最后一次发布季度财报是在 7 月 29 日。该公司报告每股收益为 0.23 美元，超出分析师一致预期的 0.18 美元，超出幅度为 0.05 美元。该公司在该季度的收入为 1.568 亿美元，而分析师预期为 1.4521 亿美元。Kiniksa Pharmaceuticals International 的净利润率为 0.90%，股本回报率为 1.05%。Kiniksa Pharmaceuticals International 已设定其 2025 财年的每股收益指导。研究分析师平均预测 Kiniksa Pharmaceuticals International 在当前财年将发布-0.55 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 的内部买卖</h2>
</div><p>In related news, insider Ross Moat sold 3,523 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $35.31, for a total transaction of $124,397.13. Following the sale, the insider owned 9,415 shares of the company's stock, valued at $332,443.65. This represents a 27.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, CAO Michael R. Megna sold 11,000 shares of the company's stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $34.84, for a total transaction of $383,240.00. Following the sale, the chief accounting officer directly owned 38,011 shares in the company, valued at approximately $1,324,303.24. The trade was a 22.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold 596,839 shares of company stock worth $20,357,964 in the last ninety days. Company insiders own 53.48% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Ross Moat 在 9 月 4 日的交易中出售了 3,523 股公司的股票。该股票以平均价格 35.31 美元出售，总交易额为 124,397.13 美元。出售后，内部人士持有 9,415 股公司股票，价值 332,443.65 美元。这代表其持股比例减少了 27.23%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，首席会计官 Michael R. Megna 在 9 月 3 日的交易中出售了 11,000 股公司的股票。该股票以平均价格 34.84 美元出售，总交易额为 383,240.00 美元。出售后，首席会计官直接持有 38,011 股公司股票，价值约 1,324,303.24 美元。该交易使其持股比例减少了 22.44%。该交易的披露信息可在此找到。在过去的九十天里，内部人士出售了 596,839 股公司股票，价值 20,357,964 美元。公司内部人士持有 53.48% 的公司股票。</p>
</div><h2>Institutional Investors Weigh In On Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>机构投资者对 Kiniksa Pharmaceuticals International 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. GAMMA Investing LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $301,000. Asset Management One Co. Ltd. purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $41,000. Wealthquest Corp purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at $42,000. Finally, AMI Asset Management Corp raised its stake in shares of Kiniksa Pharmaceuticals International by 50.3% in the first quarter. AMI Asset Management Corp now owns 77,688 shares of the company's stock valued at $1,725,000 after acquiring an additional 26,010 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 KNSA 的持仓进行了调整。GAMMA Investing LLC 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 84.8%。GAMMA Investing LLC 现在拥有 1,238 股公司股票，价值 27,000 美元，此前在该期间内增持了 568 股。Wealth Enhancement Advisory Services LLC 在第一季度购买了 Kiniksa Pharmaceuticals International 的新股份，价值 301,000 美元。Asset Management One Co. Ltd.在第一季度购买了 Kiniksa Pharmaceuticals International 的新股份，价值 41,000 美元。Wealthquest Corp 在第一季度购买了 Kiniksa Pharmaceuticals International 的新股份，价值 42,000 美元。最后，AMI Asset Management Corp 在第一季度将其在 Kiniksa Pharmaceuticals International 的股份增加了 50.3%。AMI Asset Management Corp 现在拥有 77,688 股公司股票，价值 1,725,000 美元，此前在该期间内增持了 26,010 股。对冲基金和其他机构投资者持有 53.95% 的公司股票。</p>
</div><h2>About Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>关于 Kiniksa Pharmaceuticals International</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals, Ltd.是一家生物制药公司，专注于发现、收购、开发和商业化治疗药物，以满足全球面临重大未满足医疗需求的患者的需求。其产品候选包括 ARCALYST，一种针对复发性心包炎的白介素-1α和白介素-1β，复发性心包炎是一种炎症性心血管疾病；Mavrilimumab，一种单克隆抗体抑制剂，已完成巨细胞动脉炎的二期临床试验；Vixarelimab，一种单克隆抗体，目前正在进行针对结节性瘙痒症的 2b 期临床试验，这是一种慢性炎症性皮肤病；以及 KPL-404，一种 CD40-CD154 相互作用的单克隆抗体抑制剂，这是 B 细胞成熟、免疫球蛋白类别转换和 1 型免疫反应所需的 T 细胞共刺激信号。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Kiniksa Pharmaceuticals International</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>Oracle’s AI Profits Look Slim—Are NBIS and CRWV at Risk Too?</li>
<li>Insider Trading - What You Need to Know</li>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
<li>How to Start Investing in Real Estate</li>
<li>Why Wells Fargo's Turnaround Just Hit High Gear</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Kiniksa Pharmaceuticals International 更好的股票</li>
<li>即将到来的 IPO 股票锁定期解析</li>
<li>甲骨文的 AI 利润看起来微薄——NBIS 和 CRWV 也有风险吗？</li>
<li>内幕交易 - 你需要知道的事项</li>
<li>雅培实验室十月价格暴跌是买入信号</li>
<li>如何开始投资房地产</li>
<li>为什么富国银行的转型刚刚进入高速档</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S05TQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=KNSA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Kiniksa Pharmaceuticals International 吗？</h2>
</div><p>Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Kiniksa Pharmaceuticals International 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Kiniksa Pharmaceuticals International 并不在名单上。</p>
</div><p>While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kiniksa Pharmaceuticals International 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

花旗集团将 Kiniksa Pharmaceuticals International（NASDAQ 代码：KNSA）的目标股价上调至 50.00 美元